Thursday, March 20, 2014 1:46:38 PM
Teva Copaxone Patent Reissue Yet Another Defense Strategy
2014-03-20 17:28:17.312 GMT
BI LITI NOAM LITI
Teva asked the U.S. Patent and Trademark Office to consider
reissuing the '808 patent that was invalidated in the Copaxone
litigation against Sandoz, Momenta, Mylan and Natco. Teva has
submitted new claims, amending the indefinite language objected
to by the Federal Circuit. If the patent authorities concur, the
reissue will have the same September 2015 expiry as the original
'808 patent. Teva can then file new litigation against generic
challengers.
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
